Details
Stereochemistry | ACHIRAL |
Molecular Formula | C2H5NO2 |
Molecular Weight | 75.0666 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NCC(O)=O
InChI
InChIKey=DHMQDGOQFOQNFH-UHFFFAOYSA-N
InChI=1S/C2H5NO2/c3-1-2(4)5/h1,3H2,(H,4,5)
Molecular Formula | C2H5NO2 |
Molecular Weight | 75.0666 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Glycine (Cly) is a natural amino acid neurotransmitter that acts as a co-agonist at Glutamate [NMDA] receptors in the brain and is an activator of glycine receptors, GLRA1-3, GLRB. The abnormal Gly levels have been implicated in neuropsychiatric disorders. Alterations in Gly levels are implicated in several diseases of the central nervous system. Glycine was studied in phase II of clinical trials in patients with schizophrenia. The results have shown that using of glycine was associated with reduced symptoms with promising effect sizes and a possibility of improvement in cognitive function. Besides, glycine was also studied in clinical trials phase II in children with cystic fibrosis. The clinical, spirometric and inflammatory status of subjects with cystic fibrosis improved after just 8 weeks of glycine intake, suggesting that this amino acid might constitute a novel therapeutic tool for these patients. In addition, Gly was proposed as a biomarker for brain tumor malignancy. Glycine is a component of a nutrients mixture for peripheral administration to well-nourished mildly catabolic adult patients who require only short-term parenteral nutrition.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1262868
Curator's Comment: Known to be CNS non-penetrant in rabbit. Human data not available.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094124 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28828606 |
|||
Target ID: CHEMBL5845 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17154252 |
|||
Target ID: CHEMBL5871 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17154252 |
|||
Target ID: CHEMBL1075092 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28514141 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Preventing | FREAMINE III 8.5% Approved UseAminosyn, Sulfite-Free, (a crystalline amino acid solution) infused with dextrose by peripheral vein infusion is indicated as a source of nitrogen in the nutritional support of patients with adequate stores of body fat, in whom, for short periods of time, oral nutrition cannot be tolerated, is undesirable, or inadequate. SUPPLEMENTAL ELECTROLYTES, IN ACCORDANCE WITH THE PRESCRIPTION OF THE ATTENDING PHYSICIAN, MUST BE ADDED TO AMINOSYN SOLUTIONS WITHOUT ELECTROLYTES. Aminosyn can be administered peripherally with dilute (5 to 10%) dextrose solution and I.V. fat emulsion as a source of nutritional support. This form of nutritional support can help to preserve protein and reduce catabolism in stress conditions where oral intake is inadequate. When administered with concentrated dextrose solutions with or without fat emulsions, Aminosyn is also indicated for central vein infusion to prevent or reverse negative nitrogen balance in patients where: (a) the alimentary tract, by the oral, gastrostomy or jejunostomy route cannot or should not be used; (b) gastrointestinal absorption of protein is impaired; (c) metabolic requirements for protein are substantially increased as with extensive burns and (d) morbidity and mortality may be reduced by replacing amino acids lost from tissue breakdown, thereby preserving tissue reserves, as in acute renal failure. Launch Date5.4431998E10 |
PubMed
Title | Date | PubMed |
---|---|---|
Sustained L-type calcium currents in dissociated deep dorsal horn neurons of the rat: characteristics and modulation. | 2001 |
|
Temperature-dependent separation of a delayed-onset long-lasting enhancement mediated by coactivation of NMDA and metabotropic glutamate receptors following a transient exposure of extracellular high Ca(2+). | 2001 |
|
Identification of genetic variants (g789C>T and G111S) in the human HSPB2 gene. | 2001 |
|
Identification of the first reported splice site mutation (IVS7-1G-->A) in the aminomethyltransferase (T-protein) gene (AMT) of the glycine cleavage complex in 3 unrelated families with nonketotic hyperglycinemia. | 2001 |
|
Is the Ala138Gly alteration of MEFV gene important for amyloidosis? | 2001 |
|
Differences in phosphorylation of human and chicken stathmin by MAP kinase. | 2001 |
|
Conversion of the ion selectivity of the 5-HT(3a) receptor from cationic to anionic reveals a conserved feature of the ligand-gated ion channel superfamily. | 2001 Apr 6 |
|
Towards developing a non-SnCl2 formulation for RP444, a new radiopharmaceutical for thrombus imaging. | 2001 Feb |
|
The effect of amino acid spacers on the antigenicity of dimeric peptide--inducing cross-reacting antibodies to a cell surface protein antigen of Streptococcus mutans. | 2001 Feb |
|
The folate cycle and disease in humans. | 2001 Feb |
|
Distribution of transcripts for the brain-specific GDP/GTP exchange factor collybistin in the developing mouse brain. | 2001 Feb |
|
Atypical neural messengers. | 2001 Feb |
|
Differential actions of PKA and PKC in the regulation of glutamate release by group III mGluRs in the entorhinal cortex. | 2001 Feb |
|
Glycine supply to human enterocytes mediated by high-affinity basolateral GLYT1. | 2001 Feb |
|
Amino acid interconversions in the fetal-placental unit: the animal model and human studies in vivo. | 2001 Feb |
|
Antisense treatment directed against mutated Ki-ras in human colorectal adenocarcinoma. | 2001 Feb |
|
Hamster sperm glycine receptor: evidence for its presence and involvement in the acrosome reaction. | 2001 Feb |
|
Biosynthesis of threonine from homoserine by mixed rumen microorganisms: an in vitro study. | 2001 Feb |
|
Optical approaches to embryonic development of neural functions in the brainstem. | 2001 Feb |
|
Spectral integration in the inferior colliculus: role of glycinergic inhibition in response facilitation. | 2001 Feb 1 |
|
Trimethylamine oxide counteracts effects of hydrostatic pressure on proteins of deep-sea teleosts. | 2001 Feb 15 |
|
Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes. | 2001 Feb 15 |
|
Evidence for microvesicular storage and release of glycine in rodent pinealocytes. | 2001 Feb 16 |
|
Replacement of the axial histidine ligand with imidazole in cytochrome c peroxidase. 1. Effects on structure. | 2001 Feb 6 |
|
New polymorphisms in the interleukin-10 gene--relationships to myocardial infarction. | 2001 Jan |
|
Generalized dystrophic epidermolysis bullosa: identification of a novel, homozygous glycine substitution, G2031S, in exon 73 of COL7A1 in monozygous triplets. | 2001 Jan |
|
A missense mutation encoding cys(67) --> gly in neurophysin ii is associated with early onset autosomal dominant neurohypophyseal diabetes insipidus. | 2001 Jan |
|
cAMP-dependent presynaptic regulation of spontaneous glycinergic IPSCs in mechanically dissociated rat spinal cord neurons. | 2001 Jan |
|
Excitatory amino acid concentrations in ventricular cerebrospinal fluid after severe traumatic brain injury in infants and children: the role of child abuse. | 2001 Jan |
|
Disorders of membrane channels or channelopathies. | 2001 Jan |
|
Spatial scale and cellular substrate of contrast adaptation by retinal ganglion cells. | 2001 Jan |
|
Neither GABA(A) nor strychnine-sensitive glycine receptors are the sole mediators of MAC for isoflurane. | 2001 Jan |
|
Analysis of glycoconjugate patterns of normal and hormone-induced dysplastic Noble rat prostates, and an androgen-independent Noble rat prostate tumor, by lectin histochemistry and protein blotting. | 2001 Jan 1 |
|
Regulation of a mammalian Shaker-related potassium channel, hKv1.5, by extracellular potassium and pH. | 2001 Jan 12 |
|
Crystal structure of soybean proglycinin A1aB1b homotrimer. | 2001 Jan 12 |
|
Crystal structure of an enzyme-substrate complex provides insight into the interaction between human arylsulfatase A and its substrates during catalysis. | 2001 Jan 12 |
|
Intensity-dependent, rapid activation of presynaptic metabotropic glutamate receptors at a central synapse. | 2001 Jan 15 |
|
Three pairs of cysteine residues mediate both redox and zn2+ modulation of the nmda receptor. | 2001 Jan 15 |
|
Chemical rescue of phosphoryl transfer in a cavity mutant: a cautionary tale for site-directed mutagenesis. | 2001 Jan 16 |
|
Virol A, a toxic trans-polyacetylenic alcohol of Cicuta virosa, selectively inhibits the GABA-induced Cl(-) current in acutely dissociated rat hippocampal CA1 neurons. | 2001 Jan 19 |
|
Ultrastructural evidence for direct projections from the pontine micturition center to glycine-immunoreactive neurons in the sacral dorsal gray commissure in the cat. | 2001 Jan 22 |
|
The p57Kip2 cyclin kinase inhibitor is expressed by a restricted set of amacrine cells in the rodent retina. | 2001 Jan 22 |
|
Engineering conformational flexibility in the lactose permease of Escherichia coli: use of glycine-scanning mutagenesis to rescue mutant Glu325-->Asp. | 2001 Jan 23 |
|
Effect of extracellular long-time microperfusion of high concentrations of glutamate and glycine on picrotoxin seizure thresholds in the hippocampus of freely moving rats. | 2001 Jan 5 |
|
Genetics, an alternative way to discover, characterize and understand ion channels. | 2001 Jan-Feb |
|
Functional reconstitution and characterization of recombinant human alpha 1-glycine receptors. | 2001 Jun 15 |
|
Glycine reduces novelty- and methamphetamine-induced locomotor activity in neonatal ventral hippocampal damaged rats. | 2001 Mar |
|
Functional coexpression of excitatory mGluR1 and mGluR5 on striatal cholinergic interneurons. | 2001 Mar |
|
Substrate and inhibitor specificities for human monoamine oxidase A and B are influenced by a single amino acid. | 2001 Mar 30 |
|
Amino acid residue penultimate to the amino-terminal gly residue strongly affects two cotranslational protein modifications, N-myristoylation and N-acetylation. | 2001 Mar 30 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/29246256
Daily oral supplement of glycine at a dose of 0.5 g/kg divided in three doses during 8 weeks
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15388434
The excess of glycine inhibits the growth of many bacteria, and it is used as a nonspecific antiseptic agent due to its low level of toxicity in animals. The MIC at which 90% of strains are inhibited for glycine was almost 2.5 mg/ml for 31 strains of H. pylori, including CLR-resistant strains.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 22:45:54 UTC 2023
by
admin
on
Wed Jul 05 22:45:54 UTC 2023
|
Record UNII |
TE7660XO1C
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
25922-6
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
CFR |
21 CFR 520.1060
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
LOINC |
2389-5
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
LOINC |
2390-3
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
JECFA EVALUATION |
GLYCINE
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
LOINC |
13750-5
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
CFR |
21 CFR 172.320
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
LOINC |
47635-8
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
LOINC |
56681-0
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
WHO-ATC |
B05CX03
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
LOINC |
47636-6
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
LOINC |
15135-7
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
LOINC |
32244-6
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
LOINC |
16919-3
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
LOINC |
2392-9
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
LOINC |
47639-0
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
CFR |
21 CFR 170.50
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
LOINC |
22650-6
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
LOINC |
25431-8
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
LOINC |
20644-1
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
LOINC |
47638-2
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
LOINC |
44365-5
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
LOINC |
13397-5
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
LOINC |
30066-5
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
LOINC |
47634-1
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
LOINC |
26929-0
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
LOINC |
26807-8
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
LOINC |
27325-0
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
LOINC |
32245-3
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
LOINC |
47637-4
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
LOINC |
25921-8
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
CFR |
21 CFR 310.532
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
CFR |
21 CFR 582.5049
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
LOINC |
47633-3
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
LOINC |
55862-7
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
CFR |
21 CFR 331.11
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
LOINC |
22709-0
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
DSLD |
177 (Number of products:5)
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
LOINC |
15143-1
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
LOINC |
2391-1
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
LOINC |
2393-7
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
DSLD |
92 (Number of products:1270)
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
LOINC |
22718-1
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
CFR |
21 CFR 331.15
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
WHO-VATC |
QB05CX03
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
||
|
CFR |
21 CFR 172.812
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
TE7660XO1C
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
PRIMARY | |||
|
SUB12000MIG
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
PRIMARY | |||
|
15428
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
PRIMARY | |||
|
GLYCINE
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
PRIMARY | |||
|
100000091968
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
PRIMARY | |||
|
630
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
PRIMARY | |||
|
D005998
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
PRIMARY | |||
|
C524
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
PRIMARY | |||
|
750
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
PRIMARY | |||
|
TE7660XO1C
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
PRIMARY | |||
|
495
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
PRIMARY | |||
|
25936
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
PRIMARY | |||
|
DTXSID9020667
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
PRIMARY | |||
|
CHEMBL773
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
PRIMARY | |||
|
56-40-6
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
PRIMARY | |||
|
M5796
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
PRIMARY | Merck Index | ||
|
29947
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
PRIMARY | |||
|
57305
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
PRIMARY | |||
|
DB00145
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
PRIMARY | |||
|
4919
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
PRIMARY | RxNorm | ||
|
1319
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
PRIMARY | |||
|
1295800
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
PRIMARY | |||
|
200-272-2
Created by
admin on Wed Jul 05 22:45:54 UTC 2023 , Edited by admin on Wed Jul 05 22:45:54 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR |
Binding assay
IC50
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR |
IC50
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|